Virtual triplets: The next step in personalized and ethical drug development
Learn how virtual triplets, linking PBPK, QSP, and organ-on-a-chip technologies, are transforming model-informed drug development,…
Certara2025 年 12 月 9 日
Why Upgrade to Marvin? Unlocking Speed, Accuracy, and Scientific Intelligence
Watch this webinar to see how Marvin outperforms Marvin JS with faster chemical drawing, advanced…
Certara2025 年 12 月 8 日
Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings
Certara launches an expedited Pharmacometrics (PMx) Regulatory Submission service that cuts submission timelines in half.
Certara2025 年 12 月 3 日
Modeling amyloid plaque turnover dynamics improves characterization of drug effects
Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…
Certara2025 年 11 月 26 日
10 Strategic Foundations for Early Drug Development
探索有效的早期药物研发策略，从容而清晰地推进早期研发工作。Download…
Certara2025 年 11 月 26 日
Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®
Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…
Certara2025 年 11 月 13 日
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema
Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…
Certara2025 年 11 月 12 日
Supporting KalVista’s NDA Submission for a Novel HAE Treatment
To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…
Danielle Pillsbury2025 年 11 月 12 日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025 年 11 月 10 日
